Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Eur J Pharmacol
; 898: 173988, 2021 May 05.
Article
in English
| MEDLINE | ID: covidwho-1116626
ABSTRACT
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Platelet Aggregation Inhibitors
/
Valproic Acid
/
Histone Deacetylase Inhibitors
/
Fibrinolytic Agents
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Limits:
Animals
/
Humans
Language:
English
Journal:
Eur J Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
J.ejphar.2021.173988
Similar
MEDLINE
...
LILACS
LIS